These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 7583389)

  • 1. Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response.
    Ruymann FB; Vietti T; Gehan E; Wiener E; Wharam M; Newton WA; Maurer H
    J Pediatr Hematol Oncol; 1995 Nov; 17(4):331-7. PubMed ID: 7583389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A feasibility, toxicity, and early response study of etoposide, ifosfamide, and vincristine for the treatment of children with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS) IV pilot study.
    Arndt C; Tefft M; Gehan E; Anderson J; Jenson M; Link M; Donaldson S; Breneman J; Wiener E; Webber B; Maurer H
    J Pediatr Hematol Oncol; 1997; 19(2):124-9. PubMed ID: 9149741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.
    Breitfeld PP; Lyden E; Raney RB; Teot LA; Wharam M; Lobe T; Crist WM; Maurer HM; Donaldson SS; Ruymann FB
    J Pediatr Hematol Oncol; 2001 May; 23(4):225-33. PubMed ID: 11846301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.
    Raney RB; Anderson JR; Barr FG; Donaldson SS; Pappo AS; Qualman SJ; Wiener ES; Maurer HM; Crist WM
    J Pediatr Hematol Oncol; 2001 May; 23(4):215-20. PubMed ID: 11846299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the soft tissue sarcoma committee of the children's oncology group.
    Spunt SL; Smith LM; Ruymann FB; Qualman SJ; Donaldson SS; Rodeberg DA; Anderson JR; Crist WM; Link MP
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6072-9. PubMed ID: 15447992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
    Hawkins DS; Chi YY; Anderson JR; Tian J; Arndt CAS; Bomgaars L; Donaldson SS; Hayes-Jordan A; Mascarenhas L; McCarville MB; McCune JS; McCowage G; Million L; Morris CD; Parham DM; Rodeberg DA; Rudzinski ER; Shnorhavorian M; Spunt SL; Skapek SX; Teot LA; Wolden S; Yock TI; Meyer WH
    J Clin Oncol; 2018 Sep; 36(27):2770-2777. PubMed ID: 30091945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial.
    Le Deley MC; Paulussen M; Lewis I; Brennan B; Ranft A; Whelan J; Le Teuff G; Michon J; Ladenstein R; Marec-Bérard P; van den Berg H; Hjorth L; Wheatley K; Judson I; Juergens H; Craft A; Oberlin O; Dirksen U
    J Clin Oncol; 2014 Aug; 32(23):2440-8. PubMed ID: 24982464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Intergroup Rhabdomyosarcoma Study-I. A final report.
    Maurer HM; Beltangady M; Gehan EA; Crist W; Hammond D; Hays DM; Heyn R; Lawrence W; Newton W; Ortega J
    Cancer; 1988 Jan; 61(2):209-20. PubMed ID: 3275486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venoocclusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcoma. A report of the Intergroup Rhabdomyosarcoma Study Group. Childrens Cancer Group, the Pediatric Oncology Group, and the Pediatric Intergroup Statistical Center.
    Ortega JA; Donaldson SS; Ivy SP; Pappo A; Maurer HM
    Cancer; 1997 Jun; 79(12):2435-9. PubMed ID: 9191535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor response and toxicity after single high-dose versus standard five-day divided-dose dactinomycin in childhood rhabdomyosarcoma.
    Carli M; Pastore G; Perilongo G; Grotto P; De Bernardi B; Ceci A; Di Tullio M; Madon E; Pianca C; Paolucci G
    J Clin Oncol; 1988 Apr; 6(4):654-8. PubMed ID: 3357006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.
    Arndt CA; Stoner JA; Hawkins DS; Rodeberg DA; Hayes-Jordan AA; Paidas CN; Parham DM; Teot LA; Wharam MD; Breneman JC; Donaldson SS; Anderson JR; Meyer WH
    J Clin Oncol; 2009 Nov; 27(31):5182-8. PubMed ID: 19770373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas.
    Bramwell VH; Mouridsen HT; Santoro A; Blackledge G; Somers R; Thomas D; Sylvester R; Van Oosterom A
    Cancer Chemother Pharmacol; 1986; 18 Suppl 2():S13-6. PubMed ID: 3102089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor.
    Raney B; Ensign LG; Foreman J; Khan F; Newton W; Ortega J; Ragab A; Wharam M; Wiener E; Maurer H
    Am J Pediatr Hematol Oncol; 1994 Nov; 16(4):286-95. PubMed ID: 7978043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Walterhouse DO; Pappo AS; Meza JL; Breneman JC; Hayes-Jordan A; Parham DM; Cripe TP; Anderson JR; Meyer WH; Hawkins DS
    Cancer; 2017 Jun; 123(12):2368-2375. PubMed ID: 28211936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group.
    Gupta AA; Xue W; Harrison DJ; Hawkins DS; Dasgupta R; Wolden S; Shulkin B; Qumseya A; Routh JC; MacDonald T; Feinberg S; Crompton B; Rudzinski ER; Arnold M; Venkatramani R
    Lancet Oncol; 2024 Jul; 25(7):912-921. PubMed ID: 38936378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose ifosfamide with mesna uroprotection in Ewing's sarcoma.
    Jürgens H; Exner U; Kühl J; Ritter J; Treuner J; Weinel P; Winkler K; Göbel U
    Cancer Chemother Pharmacol; 1989; 24 Suppl 1():S40-4. PubMed ID: 2503258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of intermediate risk rhabdomyosarcoma and undifferentiated sarcoma with alternating cycles of vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide.
    Arndt CA; Nascimento AG; Schroeder G; Schomberg PJ; Neglia JP; Sencer SF; Silberman TL; Moertel CL; Tillisch JK; Miser JS
    Eur J Cancer; 1998 Jul; 34(8):1224-9. PubMed ID: 9849484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group.
    Pappo AS; Lyden E; Breitfeld P; Donaldson SS; Wiener E; Parham D; Crews KR; Houghton P; Meyer WH;
    J Clin Oncol; 2007 Feb; 25(4):362-9. PubMed ID: 17264331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The IVADo regimen--a pilot study with ifosfamide, vincristine, actinomycin D, and doxorubicin in children with metastatic soft tissue sarcoma: a pilot study of behalf of the European pediatric Soft tissue sarcoma Study Group.
    Bisogno G; Ferrari A; Bergeron C; Scagnellato A; Prete A; Alaggio R; Casanova M; D'Angelo P; Di Cataldo A; Carli M
    Cancer; 2005 Apr; 103(8):1719-24. PubMed ID: 15754335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
    Hawkins DS; Felgenhauer J; Park J; Kreissman S; Thomson B; Douglas J; Rowley SD; Gooley T; Sanders JE; Pendergrass TW
    Cancer; 2002 Sep; 95(6):1354-65. PubMed ID: 12216105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.